# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

- acknowledge government rights

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- describe diseases modulated by toxins
- discuss limitations of current antitoxins
- highlight need for better antitoxins and vaccines

## SUMMARY OF THE INVENTION

- introduce antitoxin and vaccine platform
- describe nodavirus-derived VLPs
- outline antitoxin composition
- detail anthrax antitoxin embodiment
- describe immunogenic composition
- outline decorated VLPs
- discuss multivalent immunogenic compositions
- describe immunogenic composition with multiple domains
- outline method of antitoxin therapy
- outline method of vaccinating a patient

## DETAILED DISCUSSION OF THE INVENTION

- introduce nodavirus VLPs with antitoxin activity
- describe VLP decoration with immunogen of interest
- provide example of VLP with anthrax toxin binding domain
- discuss advantages of VLPs as therapeutic and vaccine
- generalize VLP platform for vaccine development

### Making VLP Antitoxins

- introduce VLP antitoxins
- describe nodavirus-derived VLPs with heterologous molecular decoy moieties
- introduce Flock House Virus (FHV) as a preferred nodavirus
- describe FHV capsid structure and composition
- identify surface-exposed loops for insertion of foreign proteins
- describe general regions for insertion of heterologous proteins
- outline methods for engineering cDNAs corresponding to RNA2 gene
- discuss production of transgenic organisms
- introduce techniques for introducing target nucleic acids into bacterial cells
- describe methods for amplifying plasmids in bacterial cells
- outline purification methods for plasmids and VLPs
- introduce baculovirus expression system for producing VLPs
- describe advantages of baculovirus expression system
- introduce insect cell lines for baculovirus expression
- describe methods for expressing recombinant nodavirus capsid protein
- outline methods for producing VLPs using baculovirus expression system
- introduce stable transfected insect cells for VLP production
- describe VLPs that include heterologous domains
- outline applications of VLPs as molecular decoys or vaccine platforms
- describe example of VLPs as anthrax antitoxins
- introduce VLP antitoxins
- describe diphtheria toxin binding
- describe botulism toxin binding
- decorate VLPs with bound heterologous immunogens
- bind heterologous immunogens to heterologous domains on VLPs
- describe use of universal adaptor/linker domains
- describe making multivalent vaccine compositions
- describe binding immunogen to VLP
- describe co-expression of immunogen and VLP
- describe isolation of VLPs and immunogens
- describe decoration of VLPs with various immunogens
- describe VLPs displaying F1 and/or V protein
- describe VLPs as anthrax vaccines
- describe multivalent display of ANTXR2 VWA domain
- describe conservative variations of nucleic acid constructs

### Sequence Variations

- introduce ANTRX2 polypeptides and nucleic acids
- describe silent variations of nucleic acids
- explain codon table and genetic code
- provide examples of silent variations
- introduce mutational derivatives of nucleic acid and protein sequences
- describe methods for mutation formats
- provide references for mutation formats
- discuss modulation of serum half-life and other properties of VLPs and immunogens

### Pharmaceutical Compositions and Administration to Patients

- introduce pharmaceutical compositions of antitoxins and immunogenic compositions
- describe formulation of pharmaceutical compositions
- discuss route of administration
- provide examples of pharmaceutical compositions for oral administration
- describe pharmaceutical compositions for intravenous, cutaneous, or subcutaneous injection
- discuss administration of VLP antitoxins or immunogenic compositions
- introduce prophylactically and therapeutically effective amounts
- discuss administration to human patients and non-human veterinary patients

## DEFINITIONS

- define technical terms
- introduce antitoxin definition
- define anthrax antitoxin
- explain anthrax toxin
- define anthrax protective antigen
- introduce capillary morphogenesis gene 2
- define extracellular von Willebrand Factor A domain
- explain heterologous domain
- define nodavirus-derived virus like particle
- introduce virus like particles and viral nanoparticles
- define corresponding amino acid residue

## EXAMPLES

- provide illustrative examples

### Example 1

- introduce anthrax antitoxin and vaccine
- describe Flock House virus platform
- design FHV-VWAANTXR2 chimeric proteins
- express and purify chimeric proteins
- analyze chimeric VLPs by SDS-PAGE and EM
- perform structural analysis of FHV-VWAANTXR2 VLPs
- model PA binding to VWA domains on VLPs
- test FHV-VWAANTXR2 VLPs for protection of cultured cells
- compare inhibitory activity of chimera 264 and sANTXR2
- test chimera 264 for protection of rats from lethal toxin challenge
- discuss therapeutic potency of chimera 264
- summarize computational models of PA bound to FHV-VWAANTXR2 particles
- introduce FHV-VWAANTXR2 particles as vaccine platform
- describe preparation of particle-PA complex
- summarize immunogenicity studies
- discuss results of ELISA assay
- describe protection against LeTx challenge
- discuss significance of multivalent display of PA
- describe advantages over monovalent PA
- discuss potential for rapid production of neutralizing antibodies
- describe safety profile of chimeric particles
- discuss potential for polyvalency to increase affinity
- describe potential for displaying additional anthrax antigens
- summarize development of reagent with dual purpose in combating B. anthracis infection
- describe cell infection and propagation
- detail VLP purification
- outline electron microscopy
- describe electron cryomicroscopy and image reconstruction
- generate pseudoatomic models
- quantify PA83 bound to chimeras
- describe cell intoxication assay
- detail macrophage-based toxin neutralization assay
- outline toxin neutralization assay
- describe LeTx challenge with FHV-VWAANTRX2 VLPs
- perform statistical analysis
- prepare FHV-VWAANTRX2 chimera 264-PA83 complexes
- describe rat immunization and LeTx challenge
- introduce Flock House virus coat protein
- describe protein data bank and virus particle explorer
- present figure legends for example 1
- show dose response curve for antitoxin concentration
- display pseudoatomic models of FHV-VWAANTXR2 chimeras
- illustrate in silico model of PA83 bound to FHV-VWAANTXR2 chimeras
- quantify PA83 bound to chimera 206 and chimera 264
- reference Manayani et al. (2007) for relevant example details
- list numbered references for example 1 and above
- describe anthrax toxin and its effects
- discuss anthrax toxin receptors and their functions
- present various studies on anthrax toxin and its receptors
- describe the structure and function of nodavirus particles
- discuss the use of recombinant baculoviruses in synthesizing morphologically distinct virus-like particles
- reference various studies on anthrax vaccine and therapy
- conclude with a discussion on the design of polyvalent inhibitors of anthrax and cholera toxins

### Example 2

- introduce combination vaccines
- motivate multivalent platform
- describe VNI-based multivalent platform
- generate PA-Ricin fusion protein
- generate PA-botulinum fusion protein
- verify correct folding of PA-R and PA-B
- scale up and purify PA-fusion proteins
- decorate VNI with PA fusion proteins
- determine binding stoichiometry
- immunize mice with VNI-PA-R and VNI-PA-B
- measure antibody response to vaccination
- test antibodies for toxin neutralization
- determine which steps in intoxication are blocked
- perform in vivo spore or toxin challenge
- determine if combination or cocktail of particles induces neutralizing immunity
- generate chimeric particle with PA-R and PA-B
- immunize with chimeric particle and challenge with each pathogen
- discuss implications and future directions

